[1] [1] VAN DE DONK N, PAWLYN C, YONG K L. Multiple myeloma[J]. Lancet, 2021, 397(10272): 410-427.

[2] [2] COWAN A J, GREEN D J, KWOK M, et al. Diagnosis and management of multiple myeloma: a review[J]. Jama, 2022, 327(5): 464-477.

[3] [3] PADALA S A, BARSOUK A, BARSOUK A, et al. Epidemiology, staging, and management of multiple myeloma[J]. Med Sci (Basel), 2021, 9(1): 3.

[4] [4] WANG S, XU L, FENG J, et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis[J]. Front Oncol, 2019, 9: 1513.

[5] [5] WALLINGTON-BEDDOE C T, MYNOTT R L. Prognostic and predictive biomarker developments in multiple myeloma[J]. J Hematol Oncol, 2021, 14(1): 151.

[6] [6] ROY S, TRINCHIERI G. Microbiota: a key orchestrator of cancer therapy[J]. Nat Rev Cancer, 2017, 17(5): 271-285.

[7] [7] KHANNA S, TOSH P K. A clinician's primer on the role of the microbiome in human health and disease[J]. Mayo Clin Proc, 2014, 89(1): 107-114.

[8] [8] DZUTSEV A, GOLDSZMID R S, VIAUD S, et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy[J]. Eur J Immunol, 2015, 45(1): 17-31.

[9] [9] YANG W, CONG Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases[J]. Cell Mol Immunol, 2021, 18(4): 866-877.

[10] [10] ROOKS M G, GARRETT W S. Gut microbiota, metabolites and host immunity[J]. Nat Rev Immunol, 2016, 16(6): 341-352.

[11] [11] SHIM J A, RYU J H, JO Y, et al. The role of gut microbiota in T cell immunity and immune mediated disorders[J]. Int J Biol Sci, 2023, 19(4): 1178-1191.

[12] [12] ROUTY B, GOPALAKRISHNAN V, DAILLRE R, et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018, 15(6): 382-396.

[13] [13] EMDIN C A, KHERA A V, KATHIRESAN S. Mendelian randomization[J]. Jama, 2017, 318(19): 1925-1926.

[14] [14] BOWDEN J, HOLMES M V. Meta-analysis and Mendelian randomization: a review[J]. Res Synth Methods, 2019, 10 (4): 486-496.

[15] [15] KURILSHIKOV A, MEDINA-GOMEZ C, BACIGALUPE R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition[J]. Nat Genet, 2021, 53(2): 156-165.

[16] [16] LOPERA-MAYA E A, KURILSHIKOV A, VAN DER GRAAF A, et al. Effect of host genetics on the gut microbiome in 7 738 participants of the Dutch Microbiome Project[J]. Nat Genet, 2022, 54(2): 143-151.

[17] [17] SEKULA P, DEL GRECO M F, PATTARO C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. J Am Soc Nephrol, 2016, 27(11): 3253-3265.

[18] [18] BURGESS S, THOMPSON S G. Avoiding bias from weak instruments in Mendelian randomization studies[J]. Int J Epidemiol, 2011, 40(3): 755-764.

[19] [19] XU J, ZHANG S, TIAN Y, et al. Genetic causal association between iron status and osteoarthritis: a two-sample Mendelian randomization[J]. Nutrients, 2022, 14(18): 3683.

[20] [20] SHEN Y, LIU H, MENG X, et al. The causal effects between gut microbiota and hemorrhagic stroke: a bidirectional two-sample Mendelian randomization study[J]. Front Microbiol, 2023, 14: 1290909.

[21] [21] LI P, WANG H, GUO L, et al. Association between gut micro-biota and preeclampsia-eclampsia: a two-sample Mendelian randomization study[J]. BMC Med, 2022, 20(1): 443.

[22] [22] HEMANI G, TILLING K, DAVEY SMITH G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data[J]. PLoS Genet, 2017, 13(11): e1007081.

[23] [23] SANDERSON E. Multivariable Mendelian randomization and mediation[J]. Cold Spring Harb Perspect Med, 2021, 11(2): a038984.

[24] [24] O'HARA A M, SHANAHAN F. The gut flora as a forgotten organ[J]. EMBO Rep, 2006, 7(7): 688-693.

[25] [25] LEBER A, HONTECILLAS R, TUBAU-JUNI N, et al. NLRX1 modulates immunometabolic mechanisms controlling the hostgut microbiota interactions during inflammatory bowel disease[J]. Front Immunol, 2018, 9: 363.

[26] [26] GUO M, HE S, SONG W, et al. The Lachnospiraceae-butyric acid axis and its role in glucocorticoid-associated osteonecrosis[J]. J Transl Med, 2024, 22(1): 1015.

[27] [27] RODRGUEZ-GARCA A, ARROYO A, GARCA-VICENTE R, et al. Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma[J]. Clin Cancer Res, 2024, 30(4): 904-917.

[28] [28] HAERZSCHEL A, CATUSSE J, HUTTERER E, et al. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia[J]. Ann Hematol, 2016, 95(12): 1979-1988.

[29] [29] LOPES R, CAETANO J, FERREIRA B, et al. The immune microenvironment in multiple myeloma: friend or foe?[J]. Cancers (Basel), 2021, 13(4): 625.

[30] [30] TOGASHI Y, SHITARA K, NISHIKAWA H. Regulatory T cells in cancer immunosuppression-implications for anticancer therapy[J]. Nat Rev Clin Oncol, 2019, 16(6): 356-371.

[31] [31] VIGNALI D A, COLLISON L W, WORKMAN C J. How regulatory T cells work[J]. Nat Rev Immunol, 2008, 8(7): 523-532.

[32] [32] EBRAHIMI-NIK H, CORWIN W L, SHCHEGLOVA T, et al. CD11c (+) MHCⅡ(lo) GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma[J]. Cancer Immunol Immunother, 2018, 67(9): 1449-1459.

[33] [33] LIU P, WANG Y, YANG G, et al. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis[J]. Pharmacol Res, 2021, 165: 105420.

[34] [34] MATERA G, MUTO V, VINCI M, et al. Receptor recognition of and immune intracellular pathways for veillonella parvula lipopolysaccharide[J]. Clin Vaccine Immunol, 2009, 16 (12): 1804-1809.

[35] [35] SHARONOV G V, SEREBROVSKAYA E O, YUZHAKOVA D V, et al. B cells, plasma cells and antibody repertoires in the tumour microenvironment[J]. Nat Rev Immunol, 2020, 20 (5): 294-307.

[36] [36] HUANG S, ZHANG X, WEI Y, et al. Checkpoint CD24 function on tumor and immunotherapy[J]. Front Immunol, 2024, 15: 1367959.

[37] [37] RODRIGUEZ-CRUZ A, VESIN D, RAMON-LUING L, et al. CD3(+) macrophages deliver proinflammatory cytokines by a CD3- and transmembrane TNF-dependent pathway and are increased at the BCG-infection site[J]. Front Immunol, 2019, 10: 2550.

[38] [38] PENG H Y, WANG L, DAS J K, et al. Control of CD4(+) T cells to restrain inflammatory diseases via eukaryotic elongation factor 2 kinase[J]. Signal Transduct Target Ther, 2023, 8 (1): 415.

[39] [39] VILLARINO A V, KANNO Y, FERDINAND J R, et al. Mechanisms of Jak/STAT signaling in immunity and disease[J]. J Immunol, 2015, 194(1): 21-27.

[41] [41] OHUE Y, NISHIKAWA H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?[J]. Cancer Sci, 2019, 110(7): 2080-2089.